Kura Oncology Inc (NASDAQ:KURA) – Oppenheimer cut their FY2020 earnings per share estimates for shares of Kura Oncology in a report issued on Monday, December 16th, according to Zacks Investment Research. Oppenheimer analyst J. Olson now anticipates that the company will post earnings per share of ($1.56) for the year, down from their previous forecast of ($1.43). Oppenheimer also issued estimates for Kura Oncology’s Q4 2020 earnings at ($0.46) EPS, FY2021 earnings at ($1.48) EPS, FY2022 earnings at ($0.68) EPS and FY2023 earnings at $0.35 EPS.
Other equities analysts have also recently issued reports about the company. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price target on shares of Kura Oncology in a research note on Monday, December 16th. Cowen reissued a “buy” rating on shares of Kura Oncology in a research note on Friday, December 6th. Zacks Investment Research lowered Kura Oncology from a “hold” rating to a “sell” rating in a research report on Wednesday. BidaskClub downgraded Kura Oncology from a “hold” rating to a “sell” rating in a report on Friday, December 20th. Finally, ValuEngine raised Kura Oncology from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd. Two analysts have rated the stock with a sell rating and nine have given a buy rating to the stock. Kura Oncology presently has an average rating of “Buy” and an average target price of $25.43.
Kura Oncology stock traded down $0.05 during trading hours on Thursday, reaching $13.49. The company had a trading volume of 335,592 shares, compared to its average volume of 296,657. The company has a debt-to-equity ratio of 0.03, a current ratio of 19.29 and a quick ratio of 19.29. The company has a 50-day moving average price of $14.73 and a 200 day moving average price of $16.35. The firm has a market cap of $611.30 million, a price-to-earnings ratio of -7.84 and a beta of 2.50. Kura Oncology has a 12-month low of $12.65 and a 12-month high of $21.42.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.36) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.39) by $0.03.
Institutional investors have recently bought and sold shares of the stock. Point72 Hong Kong Ltd purchased a new stake in Kura Oncology during the second quarter valued at $25,000. Meeder Asset Management Inc. increased its position in Kura Oncology by 164.9% during the second quarter. Meeder Asset Management Inc. now owns 1,934 shares of the company’s stock valued at $38,000 after acquiring an additional 1,204 shares during the last quarter. Bank of Montreal Can increased its position in Kura Oncology by 82,066.7% during the second quarter. Bank of Montreal Can now owns 2,465 shares of the company’s stock valued at $49,000 after acquiring an additional 2,462 shares during the last quarter. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Kura Oncology by 599.0% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,824 shares of the company’s stock valued at $56,000 after acquiring an additional 2,420 shares during the last quarter. Finally, Acadian Asset Management LLC purchased a new stake in Kura Oncology during the second quarter valued at $59,000. Institutional investors own 88.72% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company’s lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia.